Lyell Immunopharma, Inc. — Director's Dealing 2025

Nov 13, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2025-11-10

Reporting Person: Lee Gary K. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-11-10	Common Stock	S	138	$16.16	Disposed	15366	Direct

Footnotes

F1: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.